Philips has maintained 2025 guidance after AI-powered innovation and sustained strength in the North American market powered Q3 comparable sales growth.
The Dutch medtech giant stated it is maintaining its fiscal year 2025 (FY25) outlook of growth between 1% to 3% following steady performance across its business segments in Q3 2025 after total revenues were revealed at €4.3bn for Q3, reflecting a drop of around 1.7% on the same period in 2024 at around €4.37bn.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
However, Philips’ comparable sales in Q3 grew 3%, with adjusted EBITDA rising by 12.3% to $531m versus $516m in Q3 2024.
Following the Q3 results, Philips revealed its outlook for FY25, reaffirming a projected value between $1.63 and $1.93 per share, comparable sales growth of 1% to 3%, and an adjusted EBITDA margin expected at the upper end of 11.3% to 11.8%.
Following the quarterly earnings release, the company’s stock on the Euronext Amsterdam exchange closed at €28.02 per share, a 0.64% dip from €28.20 at market open on 4 November.
Philips also trades on the New York Stock Exchange (NYSE) under a market bridging mechanism for foreign entities called an American Depositary Receipt (ADR). Philips shares on the NYSE rose from a $27.21 per share open to a closing price of $28.02. The company has a market cap of around $26bn.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFor comparable sales growth, Philips reported the biggest climb in its personal health segment, with a growth of 10.9%. The diagnosis and treatment segment’s comparable sales rose by 1.3% while Connected Care grew by 5.1%.
Reflecting on Q3 2025, Philips’ CEO Roy Jakobs said: “In this quarter, we maintained our momentum, with AI-powered innovations and long-term partnerships making a real difference for patients and consumers.
“We drove strong order intake and accelerated sales growth, with sustained strength in North America. We expanded margin through innovation, focused execution and cost discipline, remaining firmly on-track as we navigate an uncertain macro environment, including tariffs.”
While not outlining specifics, Jakobs also shared during a post-earnings conference call that Philips’ overall Q3 performance reflected investments it had made to its supply chain to mitigate the impact of China-related tariffs on its US operations.
